I mentioned in the past that Nuplazid's Sleep Study should have a "Fibromyalgia arm " do you recall that...maybe last year. I even sent IR a message about that. There are many recommendations -one is to improve sleep, if you can get them to sleep better their FM tends to improve. Currently the drug recommended for FM is Lyrica, and as you mention it has many side effects, as a matter of fact the list of side effects is almost endless. Fibromyalgia is estimated to affect 2–8% of the population. So adding a FM arm to the purposed sleep study ( don't ask when will the happen) could give some good results and who knows led to an indication or off label use for FM.
...and if you want to have a real laugh...do the comparison using the 5 yr chart...the mentioned stocks are no higher than 140+%, and Acadia is like 1567% Higher.
Haven't sold one pill yet, but in the last 3 months ACAD is 60% HIGHER compared to all those stocks the article mentions : VNDA, JNJ, LLY, PFE, BMY and XNPT
Probably just some computer generated POS If you compare all those stocks vs ACAD...ACAD beats them all last 3 mos....not to mention the 5 yr chart ACAD
OK here's my question, is the mechanism that produces hallucination and delusions in Alzheimer's Disease the same, similar or ? as in Parkinson's Disease Psychosis ? How about Schizophrenia compared to PDP ?
It was reported by my parking lot spy....but later found out it stood for Mr. Kansas City Earth Escape Orbit....boy i was PO'd.
1) BUY OUT- Who knows when this could occur, but it will make your head spin when it hits.
2) Launch USA Nuplazid in June 2016-June is only 15 days away
3) AD Psychosis Phase 2 Proof of Concept trial - Enrollment completed Mid 2016,
4) AD Psychosis Phase 2 Top line data reading out in the Q4 2016
5) AD Agitation Phase 2 on track to start Q2 2016
6) EU - Marketing Authorization Application (MAA) - Update pending reg the PIP waiver.
I don't consider most Presentations a "catalysts " unless news is expected. Please feel free to make other suggests to my list.
Well the potential of Acadia will have to be valued esp if we get positive ADP data Q4. $6B is a gift at this point. Too low if you ask me.
An interesting bid for PFE ( Don't they have a derm product already?) and seems a high price considering there is so much competition in the dermatitis, psoriasis, fungal nail sector already and many generic products. Easy buy for PFE at 5Bil, a low hanging fruit if you will. But maybe they over paid. I come from the school don't price it so high, let the other guy Over Pay. So some say AGN may have been looking at Anacor too, so PFE wants to beat out the competition with a high bid, not even waiting for the FDA approval of the main derm drug...not a great strategy. It reeks of desperation. What does this bid tell me....Many big pharma companies feeling the pressure to increase their revenue streams. And Acadia could be the next in line.
I am still thinking companies with enough cash to buy ACAD, ....MRK, JNJ, and PFE
They don't have enough for a cash offer. I am sure they could finance it, but I am not sure I would be happy with their shares.
Not sure if this is significant " news ". I have never heard of this web site. Never seen it mentioned anywhere. I think todays sp rise has more to do with the PFE thing and over sold position. Why don't you post the link ?
Type Value Conf.
resist. 39.25 2
resist. 36.06 4
resist. 35.23 2
resist. 33.98 5
resist. 32.47 3
resist. 30.73 2
resist. 29.58 6
resist. 28.21 4
supp 27.05 2
supp 25.69 2
supp 24.52 2
supp 23.63 2
supp 21.76 2
supp 20.89 3
supp 19.23 2
supp 17.32 4
Yes, despite the recent Amarin decision..having new drug rep's mention anything other than PDP and competing off label drugs should be totally restricted at this point. No need to encourage off label at this point. Lets just get the launch rolling and you watch, off label use will pick up as doctors become confident with prescribing the drug.